Literature DB >> 18197156

Is Lorazepam a treatment for neuroleptic malignant syndrome?

A Francis1, S Chandragiri, S Rizvi, M Koch, G Petrides.   

Abstract

The authors assessed the ability of lorazepam and other benzodiazepines to affect the course of neuroleptic malignant syndrome (NMS). Records of inpatients who met both stringent research criteria and criteria under the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) (n=11) or DSM-IV criteria alone (n=5) for NMS were identified. All received lorazepam or related benzodiazepines within 24 hours of NMS onset or hospital admission. The records were reviewed for resolution of clinical signs of NMS. Rigidity and fever abated within 24-48 hours, while secondary features of NMS were relieved within 64 hours. These results compared favorably with prior reports of 5-day to 10-day recovery periods. Benzodiazepine administration appeared to be well tolerated. Lorazepam and related benzodiazepines may reduce recovery time in NMS.

Entities:  

Year:  2000        PMID: 18197156     DOI: 10.1017/s1092852900013407

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  9 in total

Review 1.  Catatonia: diagnosis, classification, and treatment.

Authors:  Andrew Francis
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

Review 2.  Clinical management of neuroleptic malignant syndrome.

Authors:  V L Susman
Journal:  Psychiatr Q       Date:  2001

3.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

4.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

5.  Neuroleptic malignant syndrome: a review for neurohospitalists.

Authors:  Brian D Berman
Journal:  Neurohospitalist       Date:  2011-01

6.  Case Report: Neuroleptic malignant syndrome in a HIV-positive patient.

Authors:  Sibi Joseph; Jerry George; Mongezi Tau; Lourdes de Fatima Ibanez-Valdes; Thozama Dubula; Humberto Foyaca-Sibat
Journal:  F1000Res       Date:  2020-11-30

7.  Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam.

Authors:  Adeeb Yacoub; Andrew Francis
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

Review 8.  Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice.

Authors:  Bernardo Dell'Osso; Umberto Albert; Anna Rita Atti; Claudia Carmassi; Giuseppe Carrà; Fiammetta Cosci; Valeria Del Vecchio; Marco Di Nicola; Silvia Ferrari; Arianna Goracci; Felice Iasevoli; Mario Luciano; Giovanni Martinotti; Maria Giulia Nanni; Alessandra Nivoli; Federica Pinna; Nicola Poloni; Maurizio Pompili; Gaia Sampogna; Ilaria Tarricone; Sarah Tosato; Umberto Volpe; Andrea Fiorillo
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-30       Impact factor: 2.570

9.  Malignant Catatonia Versus Neuroleptic Malignant Syndrome.

Authors:  Saral Desai; Tinu Hirachan; Anca Toma; Adela Gerolemou
Journal:  Cureus       Date:  2021-06-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.